BACKGROUND: Depression screening in patients with cancer is recommended by major clinical guidelines, although the evidence on individual screening tools is limited for this population. Here, the authors assess and compare the diagnostic accuracy of 2 established screening instruments: the depression modules of the 9-item Patient Health Questionnaire (PHQ-9) and the Hospital Anxiety and Depression Scale (HADS-D), in a representative sample of patients with cancer. METHODS: This multicenter study was conducted with a proportional, stratified, random sample of 2141 patients with cancer across all major tumor sites and treatment settings. The PHQ-9 and HADS-D were assessed and compared in terms of diagnostic accuracy and receiver operating characteristic (ROC) curves for Diagnostic and Statistical Manual of Mental Disorders, 4th edition diagnosis of major depressive disorder using the Composite International Diagnostic Interview for Oncology as the criterion standard. RESULTS: The diagnostic accuracy of the PHQ-9 and HADS-D was fair for diagnosing major depressive disorder, with areas under the ROC curves of 0.78 (95% confidence interval, 0.76-0.79) and 0.75 (95% confidence interval, 0.74-0.77), respectively. The 2 questionnaires did not differ significantly in their areas under the ROC curves (P 5 .15). The PHQ-9 with a cutoff score 7 had the best screening performance, with a sensitivity of 83% (95% confidence interval, 78%-89%) and a specificity of 61% (95% confidence interval, 59%-63%). The American Society of Clinical Oncology guideline screening algorithm had a sensitivity of 44% (95% confidence interval, 36%-51%) and a specificity of 84% (95% confidence interval, 83%-85%). CONCLUSIONS: In patients with cancer, the screening performance of both the PHQ-9 and the HADS-D was limited compared with a standardized diagnostic interview. Costs and benefits of routinely screening all patients with cancer should be weighed carefully. Cancer 2017;123:4236-43.
INTRODUCTION
Depressed patients with cancer have a higher mortality than nondepressed patients 1, 2 and have lower health-related quality of life and compliance with cancer treatment. 3 For these reasons, the American Society of Clinical Oncology (ASCO) recommends that patients with cancer be screened for symptoms of depression throughout the trajectory of care. 4 For this purpose, ASCO recommends the depression module of the 9-item Patient Health Questionnaire (PHQ-9) based on 1 study of 4264 patients with cancer. 5 However, the generalizability of that study is limited by lack of detailed medical data, enrollment of outpatients only, and few included cancer sites.
In addition to the PHQ-9, the depression module of the Hospital Anxiety and Depression Scale (HADS-D) is widely used to screen for depression. A recent meta-analysis that included more than 20 studies concluded that the HADS-D had good screening utility but poor casefinding utility. However, it is unclear whether those results can be translated into clinical practice, because most studies were underpowered or had other substantial design issues. 6 Because some cancer symptoms and treatment side effects can closely resemble somatic symptoms of depression, accurately diagnosing depression in oncologic settings can be more difficult than in other populations. Several approaches have been suggested to reduce the number of false-positive test results, eg, by substituting somatic symptom questions with further cognitive questions or excluding somatic symptom questions altogether. 7 However, results have not been conclusive to date. 8, 9 Despite this research, there are limited data on the diagnostic accuracy of the instruments recommended; and, to the best of our knowledge, there are no studies directly comparing the PHQ-9 and the HADS-D in patients with cancer. Here, we assess the diagnostic accuracy of the PHQ-9 and the HADS-D compared with a standardized diagnostic interview in a large sample across all major tumor sites and treatment settings. We also statistically compare the receiver operating characteristics (ROCs) of these 2 questionnaires using a nonparametric approach.
MATERIALS AND METHODS
The full study protocol for this prospective, multicenter study has been published previously 10 but is briefly summarized as follows.
Patients and Design
We recruited a proportional, stratified, random sample of patients with cancer from 5 study centers based on the nationwide incidence of all cancer diagnoses in Germany. 11 The required sample size was calculated from previous data on the point-prevalence of mental disorders in this population. 12 We included patients who had a confirmed diagnosis of a malignant tumor and were ages 18 through 75 years, proficient in German, and free from cognitive or verbal impairments interfering with their ability to provide informed consent. The study received research ethics committee approval by all relevant medical associations (file numbers: Hamburg, 2768; Schleswig-Holstein, 61/ 09; Freiburg, 244/07; Heidelberg, S-228/2007-50155039; Wurzburg, 107/07; and Leipzig, 200-2007). All participants provided written informed consent in accordance with the Declaration of Helsinki, and data protection was secured conforming to German dataprotection laws ( § §27-30a BDSG 13 ). Eligible patients were asked to fill in the PHQ-9 at the participating clinic or ward and were then given a questionnaire to be completed within 2 weeks, including sociodemographic items and the Hospital Anxiety and Depression Scale (HADS) as well as prestamped return envelopes. Within 4 weeks after completing the PHQ-9, the Composite International Diagnostic Interview for Oncology (CIDI-O) was conducted by telephone.
All patients who scored 9 or higher on the PHQ-9 were assigned to the CIDI-O, as illustrated in Figure 1 . Of those who had PHQ-9 scores below 9, a random sample was selected for the CIDI-O using computer-assisted block randomization at each center.
Study interviewers were extensively trained in administering the CIDI-O in a 2-day workshop and were monitored closely and supervised throughout the study period. An experienced CIDI-O editor regularly checked all completed interviews according to a standard procedure and eliminated interviews with missing data or other errors in the data set. All interviewers were blind to questionnaire results during the interview. Because some interviewers were also involved in patient recruitment, it cannot be ruled out that they may have remembered PHQ-9 scores of those patients who they recruited in person.
Measures
Sociodemographic data were collected using standardized questionnaires. Medical information was obtained from medical charts and included cancer diagnosis (International Classification of Diseases and Related Health Problems, 10th Revision 14 ), the date of current cancer diagnosis, tumor stage (International Union Against Cancer TNM classification 15 ), treatment information, and current comorbidity.
The PHQ-9 16 is a 9-item depression module from the full Patient Health Questionnaire (PHQ) and was designed to score each of the 9 Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria of major depression on a 4-point Likert scale from "0" (not at all) to "3" (nearly every day) over the previous 2 weeks. We used the validated German version of the PHQ-9. 17 The HADS 18 is a self-report questionnaire consisting of 2 subscales designed to identify and quantify depression and anxiety in physically ill patients. Here, we evaluate the 7-item depression module (HADS-D). Depressive symptoms during the previous week are reported on a Likertscale ranging from "0" (not at all) to "3" (most of the time). The HADS-D is based on older depression criteria (ICD-9, "neurotic depression") and places less emphasis on somatic symptoms than the PHQ-9. We used the validated German version of the HADS-D. 19 We used the standardized, computer-assisted CIDI-O diagnostic interview 20 as a diagnostic reference standard for "major depressive disorder" (MDD), "any mood disorder" (AMD) (MDD, dysthymic disorder, bipolar I disorder, bipolar II disorder, single manic episode, or hypomania), or "adjustment disorder" (4-week prevalence according to DSM-IV 21 and ICD-10 14 ). The CIDI-O is a modified version of the validated, standard CIDI, 22 which was specifically adapted for patients with cancer. Supplementary questions according to DSM-IV criteria for adjustment disorders were integrated into the CIDI sections for anxiety disorders and depression to determine correlations between psychiatric symptoms and cancerrelated or treatment-related events. Patients' performance status was assessed using the Eastern Cooperative Oncology Group scale, 23 with which a patient's daily living abilities can be evaluated on a score ranging from 0 (asymptomatic) to 4 (bed-bound).
Statistical Analyses
For all analyses, HADS-D and PHQ-9 sum scores were rounded to integers. Statistical analyses were performed in the following order, using IBM SPSS Statistics, version 23 (2015; IBM Corp., Armonk, NY) and MedCalc, version 16.8 (2016; MedCalc Software, Ostend, Belgium). All tests were 2-sided with a significance level of a 5 .05. Nonresponder and CIDI-O noncompletion analyses consisted of multiple logistic regression models to calculate and test adjusted differences in age, sex, education, setting, study center, or tumor entity.
Because only about one-half of patients who had PHQ-9 scores lower than 9 were randomly allocated to the diagnostic interview, this group was underrepresented in the raw data set ( Fig. 1) . To correct this, we weighted those with PHQ-9 scores <9 who had completed the CIDI-O (N 5 1238) by randomly duplicating 1074 cases based on the exclusion/inclusion ratio at randomization (1310 excluded/1508 randomly assigned to CIDI-O), resulting in a total sample of 3215 (2141 actual cases and 1074 randomly duplicated cases).
For the final sample, data were complete for all analyzed variables except HADS-D items, because there were between 7.7% and 8.4% missing values for each item. We imputed missing item data using the expectation maximization feature in SPSS. 24 Imputation was based on age, sex, PHQ-9 sum score, and CIDI-O diagnoses of MDD, AMD, and adjustment disorder. Data were assumed to be missing completely at random based on a nonsignificant Little test (P > .05). Imputed item values <0 or >3 were set to exactly 0 or exactly 3, respectively.
Cronbach a values were calculated to assess the internal consistency of each questionnaire, and the correlation between questionnaire sum scores (Pearson r) also was calculated.
We calculated operating characteristics comprising sensitivity, specificity, Youden index, positive predictive value, negative predictive value, overall accuracy (percentage of true results), and inter-rater agreement (Cohen j) 25 for all possible cutoff points on the HADS-D and PHQ-9.
To assess the diagnostic accuracy of the HADS-D and PHQ-9, we performed ROC analyses. 26 ROC curves indicate sensitivity and specificity combined for all possible cutoff points, such that the area under the curve (AUC) is a measure of diagnostic accuracy. The interpretation of AUC values depends on the context. For our Original Article purposes, an AUC of 0.5 represents recognition by chance, and an AUC of 0.9 is considered "excellent," 0.8 is considered "good," 0.7 is considered "fair," and 0.6 is considered "poor." 27 We statistically compared the AUCs of the 2 questionnaires using a nonparametric approach. 28 If the questionnaire is used as the sole diagnostic instrument, then the optimal cutoff score should have the best trade-off between sensitivity and specificity, aggregated in the Youden index (sensitivity 1 specificity 2 1). 29 In 2-stage screening, where a positive result is followed by further diagnostics, high sensitivity (missing as few patients as possible) is more important than high specificity. For this purpose, we identified the cutoff value with the highest arithmetic mean between specificity and doubly weighted sensitivity ([2 * sensitivity 1 specificity] / 3). In addition, we assessed operating characteristics for the ASCO depression screening algorithm. 4 The guideline recommends a 2-stage process in which patients are first given 2 items from the PHQ-9 (anhedonia and depressed mood). In a second step, only those patients who score 2 on 1 or both items are asked to complete the rest of the questionnaire. Patients who score 2 on anhedonia or depressed mood and have a PHQ-9 sum score 8 are considered to have a positive screening result.
We performed sensitivity analyses to estimate the influence of the following factors on our results. The impact of weighting underrepresented cases and imputing missing HADS-D item data was assessed by repeating ROC analyses with raw data (no weighting, no imputation [N 5 2141]; between 7.7% and 8.4% missing values for individual HADS-D items). To assess the impact of including inpatients, we repeated all ROC analyses with outpatients only (N 5 580). The influence of uncertain time periods between questionnaire and interview was assessed by repeating analyses with patients for whom dates of assessment on the HADS-D and the CIDI-O interview were complete and the HADS-D had been completed fewer than 28 days before the interview or 7 days after the interview (N 5 1465 remaining patients; 23% excluded). Because of criticism that diagnostic accuracy studies have been biased by the inclusion of patients who already have a diagnosis, 30 we repeated ROC analyses excluding all patients who had a known diagnosis of depression according to their medical charts (N 5 29).
RESULTS
The overall response rate was 68% (Fig. 1) . Nonresponder analyses revealed that study participants were younger (P < .001), more educated (P < .001), and were more likely to be recruited from a cancer rehabilitation center (P < .001) than nonparticipants, as previously reported. 31 The CIDI-O noncompletion rate was 21% (95% confidence interval, 19%-22%), and noncompletion rates were negatively associated with education (P 5 .003) and age (P 5 .002). 31 Sociodemographic and medical sample characteristics are listed in Table 1 . The mean 6 standard deviation patient age was 58 6 11 years, and the mean time since current cancer diagnosis was 14 6 2 months. Patients whose tumor stage could not be determined were mostly those with unclear metastatic status (stage III or IV). Tumor sites summarized as "other" included bone (ICD-10 code C40-41; N 5 9) and thymus (code C37; N 5 4) ( Table 1) .
After weighting, the prevalence of MDD (CIDI-O diagnosis) was 5%. The prevalence rate of AMD was 7%, and adjustment disorder had a prevalence of 11%, as previously reported. 31 The distribution and severity of depressive symptoms in this sample have been reported elsewhere. 32 There was no evidence of adverse events related to the questionnaires or the interview. Internal consistency (Cronbach a) was.85 for the HADS-D and .79 for the PHQ-9, and sum scores revealed a significant correlation (r 5 0.63; P < .001).
Operating characteristics for selected cutoff levels and for the ASCO algorithm are provided in Table 2 . For diagnosing MDD, both questionnaires had fair accuracy, with AUCs of 0.78 and 0.75 for the PHQ-9 and the HADS-D, respectively (Fig. 2) . Both questionnaires performed slightly better at identifying AMD, with AUCs of 0.80 (PHQ-9) and 0.77 (HADS-D) (Supporting Table 1 and Supporting Fig. 1 ; see online supporting information), whereas performance was poor for identifying adjustment disorder, with AUCs of 0.63 and 0.62, respectively (Supporting Table 2 ; see online supporting information). The 2 questionnaires did not differ significantly in AUCs for any of the diagnostic groups (all P > .05). The best screening cutoff (with sensitivity weighted double) for MDD was 7 for the PHQ-9 and 4 for the HADS-D (Table 2 ). For MDD case finding, the highest Youden index was achieved at cutoff scores of 7 for the PHQ-9 and 6 for the HADS-D.
Our sensitivity analyses revealed differences in AUC values from 20.02 to 0.02 between raw data and each of the following factors: weighting and imputation, analyzing outpatients only, excluding patients with excessive or uncertain number of days between questionnaire and interview, and excluding patients with a known diagnosis of depression (Supporting Table 3 ; see online supporting information). When controlling for excessive or uncertain time between points of assessment (N 5 1465 remaining), the mean 6 standard deviation time between questionnaire and interview was 4 6 6 days and AUC values were 0.02 higher compared with raw data (Supporting Table 3 ; see online supporting information).
DISCUSSION
In this large, multicenter study of patients with cancer who were randomly sampled across all major cancer types and treatment settings, the PHQ-9 and the HADS-D demonstrated fair diagnostic accuracy for MDD, as illustrated by AUCs of 0.78 and 0.75, respectively. For the PHQ-9, our results suggest substantially worse diagnostic accuracy than previous studies in patients with cancer, which reported AUC values of 0.94 and 0.92. 5, 33 With regard to the HADS-D, previous AUC estimates have ranged widely, from 0.70 to 0.94, but most studies reported higher accuracy than our study. 6, 33, 34 It is conceivable that the differences between our study and previous reports arose from the inclusion of cancer inpatients, who are likely to have a higher somatic symptom burden than outpatients and thereby more overlap with somatic symptoms of depression. However, our sensitivity analyses render this unlikely (Supporting Table  3 ; see online supporting information).
It should be noted that our sample had a relatively low MDD prevalence of 5% compared with the average prevalence of 16% reported in a meta-analysis of interview-based studies among patients with cancer, although those authors acknowledged strong evidence of publication bias toward studies with high prevalence rates. 35 It is noteworthy that previous diagnostic accuracy studies observed similarly low prevalence rates of MDD (6% and 8%) but still reported much higher AUC values (0.93 and 0.94). 5, 36 The screening algorithm recommended by ASCO had only 44% sensitivity, suggesting that this algorithm may not be suitable for detecting a satisfactory proportion of depressed patients. To achieve a better level of sensitivity, our results suggest using lower cutoff scores than previously recommended. The PHQ-9 with a cutoff score 7 had the best overall screening performance in our study, whereas previous reports have recommended screening with PHQ-9 cutoff scores 8 or 10.
5,33 Of 100 patients who screened at cutoff scores 7, 41 screened positive, but only 4 of those patients received a CIDI-O diagnosis of MDD; in addition, 1 patient with MDD was not recognized through screening (Fig. 3) . In clinical practice, this would mean that almost one-half of patients with cancer would need a referral for further diagnostics to identify those who actually have major depression.
Strengths of our study include the multicenter design, the large representative sample of patients from all treatment settings, reliable clinical data from medical charts, and meaningful nonresponder analyses. Our study also has some limitations. The results may have been distorted by weighting underrepresented cases (because of reduced standard error), imputing missing HADS-D item data, or the inclusion of patients with a known diagnosis of depression. In addition, the PHQ-9, HADS-D, and CIDI-O were not administered at the same time, meaning that a patient's depressive symptoms may have changed between 2 points of assessment, resulting in lower agreement between measures. We addressed all of these issues with sensitivity analyses and observed that these factors only had a minimal impact on estimates of diagnostic accuracy. However, the application of measures was not randomized, and we were unable to independently control for the time between the PHQ-9 and CIDI-O. Because the PHQ-9 was applied before the HADS-D, the accuracy of the PHQ-9 may have been slightly underestimated compared with the HADS-D. Furthermore, we were ethically obligated to exclude patients with cognitive impairments who were unable to give informed consent, which introduced a small bias to our sample. In a clinical setting, these questionnaires may be less accurate when given to patients with cognitive impairments, because the HADS-D contains reverse items, and the PHQ-9 includes double-negatives, thus requiring a relatively high level of executive function.
Our results suggest that 2 of the most established screening questionnaires for depression may have lower diagnostic accuracy in patients with cancer than previously reported. The use of these instruments with sufficiently sensitive cutoff scores is likely to produce a large number of false-positive results. This would require a large investment of time in follow-up diagnostic tests. Therefore, in the light of scarce health care resources, costs and benefits of routine screening for all patients with cancer should be carefully weighed. Furthermore, the screening algorithm recommended by ASCO had an unsatisfactory level of sensitivity in our study, detecting fewer than one-half the depressed patients with cancer. Clinicians should not rely on screening questionnaires alone, because this poses a risk of overdiagnosis and overtreatment, with potentially detrimental effects. Instead, thoroughly trained psycho-oncologic specialists are needed to reliably diagnose depression in this population. Future research should address these issues and explore care concepts that can reliably identify care needs in a cost-effective manner. 
